Draig Therapeutics appoints Ivana Magovčević-Liebisch as President and CEO
Charlie Blackie-Kelly | November 5, 2025 | Appointment | | Draig Therapeutics, Neuropsychiatry, neuroscience
Draig Therapeutics, a Welsh clinical-stage company developing glutamate and GABA-based treatments for neuropsychiatry, has appointed Ivana Magovčević-Liebisch as President and CEO.
Magovčević-Liebisch succeeds Draig Co-Founder Ruth McKeman, who had been serving as interim CEO. McKeman will continue to support the company as a member of the Board of Directors.
Douglas E Williams, Chairman of the Board, said: “As Draig’s new President and CEO, Ivana is a fantastic addition to the team, given her strong track record in growing companies and advancing innovative product candidates for patients in need, particularly in the neuroscience space. The Board is confident that these qualities will benefit Draig as it advances the clinical development of DT-101, a differentiated AMPAR positive allosteric modulator, for people with major depressive disorder and its broader pipeline in other neuropsychiatric disorders.”
Prior to joining Draig Therapeutics, Magovčević-Liebisch was President and CEO of Vigil Neuroscience, a company she founded and led until its acquisition by Sanofi earlier this year. Under her leadership, Vigil advanced from inception and early preclinical assets to a clinical-stage organisation within 18 months, raising $350m through an IPO and subsequent investments.
She has also held senior leadership roles at Ipsen, where she served as Executive Vice President and Chief Business Officer, and at Teva Pharmaceutical Industries as Senior Vice President and Head of Global Business Development for its specialty medicines business.
Magovčević-Liebisch added: “In just a short period of time, Draig has established a strong foundation, assembled a team with exceptional talent, and developed a clear path to advance its pipeline of ground-breaking therapies for people with neuropsychiatric disorders. This company and its approach to neuropsychiatric disorders has enormous potential to develop best-in-class AMPAR- and GABAAR-based therapeutics.”
Related Content
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and …
Abbvie acquires Cerevel Therapeutics
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple …
Evotec shares progress in Bristol Myers Squibb neuroscience collaboration
Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with …
